Bài viết đánh giá tính hiệu quả và an toàn của phương pháp can thiệp nút mạch cầm máu trong điều trị bệnh nhân (BN) chảy máu tá tràng cấp tính. Đối tượng và phương pháp nghiên cứu: Nghiên cứu hồi cứu/tiến cứu mô tả từ 01/01/2020 đến 31/05/2021, 21 BN được chẩn đoán chảy máu tá tràng và can thiệp nội mạch cầm máu tại Bệnh viện Hữu nghị Việt Đức | vietnam medical journal n02 - OCTOBER - 2021 of pembrolizumab as first-line therapy for 8. She L. et al 2019 quot Cost-effectiveness analysis advanced non-small cell lung cancer quot Lung of pembrolizumab versus chemotherapy as first- Cancer 124 pp. 248-254. line treatment in locally advanced or metastatic 4. Huang M et al 2019 quot Cost effectiveness of non-small cell lung cancer with PD-L1 tumor pembrolizumab versus chemotherapy as first-line proportion score 1 or greater quot Lung Cancer. treatment in PD-L1-positive advanced non-small- 138 pp. 88-94. cell lung cancer in the USA quot Immunotherapy 9. Wan N. et al 2020 quot Cost-effectiveness analysis 11 17 pp. 1463 1479. of pembrolizumab plus chemotherapy with PD-L1 5. Huang M. et al 2017 quot Cost Effectiveness of test for the first-line treatment of NSCLC Cancer Pembrolizumab vs. Standard-of-Care Med 9 5 pp. 1683-1693. Chemotherapy as First-Line Treatment for B. et al 2020 quot The effect of PD-L1 Metastatic NSCLC that Expresses High Levels of categories-directed pembrolizumab plus PD-L1 in the United States quot Pharmacoeconomics chemotherapy for newly diagnosed metastatic non- 35 8 pp. 831-844. small-cell lung cancer a cost-effectiveness analysis quot 6. Insinga R. P. et al 2018 quot Cost-effectiveness Transl Lung Cancer Res 9 5 pp. 1770-1784. of pembrolizumab in combination with X. et al 2017 quot Cost-effectiveness chemotherapy in the 1st line treatment of non- analysis of pembrolizumab plus chemotherapy for squamous NSCLC in the US quot J Med Econ 21 12 previously untreated metastatic nonsmall cell lung pp. 1191-1205. cancer in the USA quot TheOncologist 22 pp. 1392 1399. 7. Insinga R. P. et al 2019 quot Cost-effectiveness K. et al 2019 quot Cost-effectiveness of pembrolizumab in combination with analysis of pembrolizumab monotherapy and chemotherapy versus chemotherapy and chemotherapy in the non-small-cell lung cancer pembrolizumab monotherapy in the first-line with different PD-L1
